(132 days)
Not Found
No
The summary describes standard ECG analysis techniques and signal processing (calculating RMS values of high-frequency components) without mentioning AI or ML. The analysis is based on comparing measured values to resting values and predefined protocols, which are not indicative of AI/ML.
No.
The device is intended for diagnostic purposes (detection and monitoring of cardiac conditions) and does not directly provide therapy.
Yes
The device is intended to disclose conditions like arrhythmia and myocardial ischemia, and to aid in the evaluation of myocardial ischemia, which are all diagnostic purposes.
No
The device description explicitly states it is a "compact monitor for measuring, processing, storing, and displaying information derived from... Electrocardiogram (ECG)." This indicates the device includes hardware components for acquiring and displaying physiological measurements, not just software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In Vitro Diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device function: The HyperQ™ System measures and analyzes physiological signals (ECG) directly from the patient's body. It does not analyze samples taken from the body.
- Intended Use: The intended use describes monitoring and analyzing the electrical activity of the heart during rest and stress, which is a direct physiological measurement.
Therefore, the device falls under the category of a medical device that performs physiological monitoring and analysis, rather than an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
ECG is intended to disclose either normal condition or patterns of arrhythmia, myocardial ischemia, rate abnormalities, or features of prognostic value in the following cases:
- Patients with suspected cardiac abnormalities o
- Populations of patients at an age or period in which a routine baseline . evaluation of ECG characteristics is desired.
Stress testing is the most widely used method to decide whether this chest pain is related to myocardial ischemia, and thus to coronary artery disease. In stress testing, the contractile capability of the heart muscle is monitored via ECG during patient exercise. Patients exercise by bicycle, treadmill, or other means, while the ECG is monitored continuously. Exercise loads are decemined by while the LCG is momtored consignals as well as the HF-QRS signals are predenticu protocols. The LCC exginal lecovery phase portions of the exercise recorded for the resulting, enereiss, are compared to the resting protocol. The Changes in both. Desirest, changes in the high frequency of the ECO records. In the Trype Q - Sales - Sales (RMS) values, are compared to the resting values.
Most of the commercial stress test systems control the bicycle or treadmill friost of the conning to the requirements of the chosen protocol, although this is not essential.
ST segment monitoring is intended as an aid in the evaluation of myocardial ischemia in patients with known or suspected coronary artery disease. The ST segment algorithm has been tested for accuracy of the ST segment data, and a database is used as a tool for performance testing.
The significance of the ST segment changes must be determined by a physician.
The HyperQ™ Software is intended to be used as an aid to stress ECG test by means of analysis of high frequency components present within the central portion of the QRS complex.
The significance of the HF-QRS changes must be determined by a physician.
Product codes (comma separated list FDA assigned to the subject device)
MWI
Device Description
The HyperO™ System is a compact monitor for measuring, processing, storing, and displaying information derived from the following physiological measurements:
- Electrocardiogram (ECG). A twelve lead ECG is acquired and a waveform . can be displayed real-time on the LCD screen, recorded or printed. The design of the ECG function is derived directly from the predicate device, the PC ECG 1200 device.
- Detection, analyzing and recording of the high frequency components of the QRS complex of standard ECG signals.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Cardiac muscle
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Physician
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).
(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the text "Ko42981" in a bold, sans-serif font. Below this text, there is a smaller line of text that reads "C / 11". The text appears to be part of a label or identifier, possibly from a document or inventory system.
MAR 1 0 2005 510(K) SUMMARY
HYPERQTM SYSTEM
510(k) Number K
Applicant's Name:
Biological Signal Processing Ltd. 2a Habarzel Street Tel-Aviv 69710, Israel Tel.: 972-3-647 4840 Fax: 972-3-647 1498 amir(@bsp.co.il , irit(@bsp.co.il
Contact Person:
Arava HaCohen, RAC A. Stein - Regulatory Affairs Consulting 20 Hata'as St. Kfar Saba 44425 Israel Tel. + 972-9-7670002 Fax. +972-9-7668534 e-mail: ach asra@netvision.net.il
Date Prepared:
October 2004
Trade Name:
HyperQ™ System
Classification Name:
Monitor, Physiological, Patient (Without Arrhythmia Detection Or Alarms)
Establishment Registration No.:
Establishment registration form (Form FDA 2891) has been submitted but no registration number has been assigned yet.
1
Classification:
FDA has classified a Monitor, Physiological, Patient (Without Arrhythmia I DA has chassified a neenters s a class II device (product code MWI) and it is reviewed by the Cardiovascular Panel.
Predicate Device:
The HyperQ™ System is substantially equivalent to the PC ECG 1200 device (NORAV MEDICAL LTD.) cleared under K000404 in terms of intended use, (1010) Fire REDIOTE technological characteristics, performance and user interface.
The predicate device is a Class II medical device.
Performance Standards:
The HyperQTM System complies with:
U.S. Federal Performance Standard set forth in 21 CFR 898 for electrode lead wires and Patient Cables.
In addition, the device complies with the voluntary recognized standards: IEC-601-1:1988 and amendments, IEC 60601-1-2:2001, IEC 60601-2-27:1994, IEC60601-2-25:1999 and amendment, IEC 60601-1-4:1996, EC53:1995, EC38:1998 and EC11:1991.
Intended Use / Indication for Use:
ECG
ECG is intended to disclose either normal condition or patterns of arrhythmia, myocardial ischemia, rate abnormalities, or features of prognostic value in the following cases:
- Patients with suspected cardiac abnormalities o
- Populations of patients at an age or period in which a routine baseline . evaluation of ECG characteristics is desired.
Stress Testing
Angina pectoris (chest pain) is a clinical syndrome resulting from myocardial ischemia, indicative of reduced blood supply to the cardiac muscle. The electrocardiogram may establish the diagnosis of ischemic heart disease if characteristic changes are present.
Stress testing is the most widely used method to decide whether this chest pain is related to myocardial ischemia, and thus to coronary artery disease. In stress testing, the contractile capability of the heart muscle is monitored via ECG
2
V=4.202
P. 5/4
during patient exercise. Patients exercise by bicycle, treadmill, or other means, while the ECG is monitored continuously. Exercise loads are decemined by while the LCG is momtored consignals as well as the HF-QRS signals are predenticu protocols. The LCC exginal lecovery phase portions of the exercise recorded for the resulting, enereiss, are compared to the resting protocol. The Changes in both. Desirest, changes in the high frequency of the ECO records. In the Trype Q - Sales - Sales (RMS) values, are compared to the resting values.
Most of the commercial stress test systems control the bicycle or treadmill friost of the conning to the requirements of the chosen protocol, although this is not essential.
ST segment monitoring is intended as an aid in the evaluation of myocardial ischemia in patients with known or suspected coronary artery disease. The ST segment algorithm has been tested for accuracy of the ST segment data, and a database is used as a tool for performance testing.
The significance of the ST segment changes must be determined by a physician.
HyperOTM
The HyperQ™ Software is intended to be used as an aid to stress ECG test by means of analysis of high frequency components present within the central portion of the QRS complex.
The significance of the HF-QRS changes must be determined by a physician.
Device Description:
The HyperO™ System is a compact monitor for measuring, processing, storing, and displaying information derived from the following physiological measurements:
- Electrocardiogram (ECG). A twelve lead ECG is acquired and a waveform . can be displayed real-time on the LCD screen, recorded or printed. The design of the ECG function is derived directly from the predicate device, the PC ECG 1200 device.
- Detection, analyzing and recording of the high frequency components of the � QRS complex of standard ECG signals.
3
Substantial Equivalence:
There are no unique applications, indications, material or specifications Phore are "ife" and "in "and" " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " " "
-
the HyperQ™ System has the same intended use as its predicate device, ্ত and,
-- 1 .. -
the HyperQ™ System has the same technological characteristics, (i.e., o same materials, design, energy source, diagnosis algorithm and principle of operation as the predicate device, and;
-
The HyperQ™ System includes a new off-line software module that o does not raise new issues of safety or effectiveness based on previous pre-clinical and clinical studies and software validation.
Therefore, we believe that the HyperQ™ System is substantially equivalent to its predicate device cited above without raising new safety and/or effectiveness issues.
4
Image /page/4/Picture/2 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States of America. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized symbol that resembles three wavy lines or abstract figures, possibly representing people or services.
MAR I U 2005
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
BSP Ltd. c/o Arava HaCohen, RAC A. Stein Regulatory Consulting 20 Hata'as St. Kfar Saba 44425 ISRAEL
Re: K042981 Trade Name: HyperQ System Regulation Number: 21 CFR 870.2300 Regulation Number: 21 CFR 870.2500
Regulation Name: Physiological Patient Monitor (without arrhythmia detection or alarms) Regulatory Class: Class II Product Code: MWI Dated: October 24, 2004 Received: October 29, 2004
Dear Mr. HaCohen:
We have reviewed your Section 510(k) premarket notification of intent to market the indication We have reviewed your Section 910(x) premainted in the may better the indications
referenced above and have determined the device is substantial in interstate referenced above and have determined the arrest of the Madical Devices marketed in interstate for use stated in the enclosure) to regally manced promotions of the Federal Food Drug commerce prior to May 28, 1970, the charger and other conveyel and the Federal Food, Drug,
devices that have been reclassified in accordance with the provision application (P devices that have been reclassified in accordance with the previous approval applications of the Act. The and Cosmetic Act (Act) that do not require approval controls provisions of the Act. The Act. The
You may, therefore, market the device, subject to the generation, listing You may, merelore, market the devreet, belyer to the general controls provisions of the Feet mortal sequilibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it c If your device is classified (sec above) mo existing major regulations affecting your devices. EDA may may be subject to such additional controls. Existing thing of the 898. In addition, FDA may
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898 septem be found in the Code of Pederal Regarders
publish further announcements concerning your device in the Federal Register.
5
Page 2 -- Arava HaCohen, RAC
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please be advised that FDA s issuated of a but course with other requirements of the Act
that FDA has made a determination that your device complies with of manages. You must that FDA has made a determination administered by other Federal agencies. You must a or any Federal statutes and regulations daminities or registration and listing (21 l
comply with all the Act's requirements, including, but not limited to requirements as set comply with all the Act s requirements, mercessed in the practice requirements as set
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as s CFR Part 807); labeling (21 CFR Part 800); good and frapplicable, the electronic
forth in the quality systems (QS) regulation (21 CFR 1000 1950 forth in the quality systems (Sections 531-542 of the Act); 21 CFR 100-1050.
product radiation control provisions (Sections 531-542 of the Act); vary Section > product radiation control provisions (Dections of Section in your Section 10(k)
This letter will allow you to begin marketing your device of your davice to a legal This letter will anow you to begin maketing your averal equivalence of your device to a legally premarket notification. The PDA inding of subscribed on thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
rs the results of the counter and 100 and 11 and manages the roculation ent If you desire specific advice for your ac not on one of the regulation entitled, and the regulation Contact the Office of Complanes as (21) = 1) = 1 = (21 Part 807.97). You may obtain " Misoranding by reference to premanteries.its in the Act from the Division of Small other general Information on your responsion in toll-free number (800) 638-2041 or
Manufacturers, International and Consumer Assistance at the bitcomment btral Manufacturers, International and Octess http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
Dana R. Wehner
Image /page/5/Picture/5 description: The image contains a handwritten symbol that resembles a cursive letter 'G' or a simplified drawing of a crescent moon with a small loop at the bottom. The symbol is drawn with a thick line, and it appears to be isolated against a white background. The image is simple and focuses solely on the single, stylized character.
( A Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known): K042981 HyperQTM System Device Name: Indications for Use:
ECG
ECG is intended to disclose either normal condition or patterns of arthythmia, myocardial ischemia, rate abnormalities, or features of prognostic value in the following cases:
- Patients with suspected cardiac abnormalities �
- I attents with basebased and . characteristics is desired.
Stress Testing
Stress Pesting Angina pectors (chest pain) is a chilical syndrome results necessariogram may
indicative of reduced blood supply to the cardiac muscle. The economic of indicative of Treduced "Diood" supply" to "the "carateristic changes are present. "
establish the diagnosis of ischemic heart disease if characteristic changes are present.
Stress testing is the most widely used method to decide whether this chest pain is related to Stress testing is the most when ascree arery disease. In stress testing, the contractile myocardial ischemia, and thus to colonal y atent execuse. Patient exercise. Patients exercise. Patients by bicycle, treadmill, or other means, while the ECG is monitored continuously. Exercise by bicycle, treadmin, by predefined protocols. The ECG signals as well as the ORS signals are recorded for the resting, exercise, and recovery phase portions of the exercise signals are recorded for the resting, exercise, and records') po the resting ECG records. Incomes colousted protocol. The changes in both LCO warolohio are componey of the mid QRS complex, calculated the HyperQ -- stress test, changes in re compared to the resting values.
as too the commercial stress test systems control the bicycle or readmill automatically Most of the requirements of the chosen protocol, although this is not essential.
ST segment monitoring is intended as an aid in the evaluation of myocardial ischemia in ST segment monitoring is michael as an are in the ST segment algorithm has been patients with Known of suspected coronary artery and adatabase is used as a tool for performance testing. The significance of the ST segment changes must be determined by a physician.
HyperQ™M
The HyperQTM Software is intended to be used as an aid to stress ECG test by means of The HyperQ™ Software is michied to oo asser as an in in the central portion of the QRS complex.
The significance of the HF-QRS changes must be determined by a physician.
Over-The-Counter Use _ Prescription Use _____________________________________________________________________________________________________________________________________________________________ AND/OR (21 CFR 801 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Bhimmar
n Sian-I vision of Cardlov 10(k) Number k
Page 1 of 1